- The FDA grants 510(k) clearance for Sonoma Pharmaceuticals' (NASDAQ:SNOA) antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels.
- The company adds that it can also be used to relieve itching and pain from minor skin irritations, lacerations, abrasions and minor burns.
- Update: Shares are up 28% premarket on robust volume.
FDA clears Sonoma Pharma's antimicrobial post-therapy gel
Recommended For You
About SNOA Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| SNOA | - | - |
| Sonoma Pharmaceuticals, Inc. | ||